Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rVWF and rFVIII for Bleeding in Von Willebrand Disease
NCT01410227Phase 3Completed
- Sponsor
- Takeda
- Start
- Nov 2011
- Primary completion
- Feb 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 16
01
Overview
A Phase 3 trial of vonicog alfa in von Willebrand disease (VWD), sponsored by Takeda. Started Nov 2011; status: completed.
02
Drugs
vonicog alfa
03
Conditions
von Willebrand disease (VWD)
Beyond the preview
Go deeper on NCT01410227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01410227.